A team of researchers at the Hadassah Medical Center in Israel has developed a unique method of applying a patient’s own stem cells to restore mobility following progressive multiple sclerosis (MS). MS is an autoimmune disorder in which the body attacks its own neurons and affects millions of people worldwide. Severely progressive MS leads to complete loss of limb function, memory problems, seizures, and even systemic organ failure. This groundbreaking, double-blind, Phase II clinical trial successfully administered autologous (the patient’s own) mesenchymal stem cells, which were cultured and expanded to clinically significant numbers, and then applied directly into the spinal fluid. The treatment simultaneously addressed the two problems of MS - inflammatory immune response and the destruction of the outer coating of neurons that allows for quick signal transduction thereby engendering a significant increase in efficacy.